RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)

RBC Capital analyst Conor McNamara maintained a Buy rating on QuidelOrtho (QDEL – Research Report) today and set a price target of $68.00. The company’s shares closed yesterday at $42.68.

According to TipRanks, McNamara is an analyst with an average return of -10.8% and a 33.67% success rate. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Maravai Lifesciences Holdings, and Bio-Rad Laboratories.

Currently, the analyst consensus on QuidelOrtho is a Hold with an average price target of $54.20.

QDEL market cap is currently $2.85B and has a P/E ratio of -275.35.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of QDEL in relation to earlier this year. Last month, Kenneth Buechler, a Director at QDEL bought 9,041.00 shares for a total of $190,493.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

QuidelOrtho (QDEL) Company Description:

Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.